Author

Peter Wolf

University of GrazPrimary ORCID profile (0000-0001-7777-9444 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Peter WolfiD3 papers · Medical University of Graz

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Helena SorgeriD· 1 shared Isabella PerchthaleriD· 1 shared Lukas KenneriD· 1 shared Martin Lothar MetzelderiD· 1 shared Michaela SchledereriD· 1 shared Richard MoriggliD· 1 shared Saptaswa DeyiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Helena SorgerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting the hyperactive STAT3/5 pathway in cutaneous T-cell lymphoma with the multi-kinase nuclear transporter inhibitor IQDMA

Saptaswa Dey, Helena Sorger, Michaela Schlederer, Isabella Perchthaler, Martin Lothar Metzelder, Lukas Kenner, Richard Moriggl, Peter Wolf

This study evaluates IQDMA, a multi-kinase inhibitor, as a targeted therapy for cutaneous T-cell lymphoma, showing significant tumor volume reduction and STAT3/5 pathway inhibition compared to PUVA.

bioRxiv · Mar 3, 2025 · PreprintCancer Biology